{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=78",
    "query": {
      "condition": "Gastrointestinal Carcinoma",
      "page": 78
    },
    "page_size": 10
  },
  "pagination": {
    "page": 78,
    "page_size": 10,
    "total_count": 2732,
    "total_pages": 274,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=79&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=77&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T17:33:55.022Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03998033",
      "title": "Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Liver Cancer",
        "Liver Neoplasm",
        "Metastatic Liver Cancer"
      ],
      "interventions": [
        {
          "name": "ET140202 autologous T cell product",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eureka Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-05-30",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Irvine, California • Sacramento, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03998033"
    },
    {
      "nct_id": "NCT03037385",
      "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "RET-altered Non Small Cell Lung Cancer",
        "Medullary Thyroid Cancer",
        "RET-altered Papillary Thyroid Cancer",
        "RET-altered Colon Cancer",
        "RET-altered Solid Tumors",
        "Lung Neoplasm",
        "Carcinoma, Non-Small-Cell Lung",
        "Thyroid Diseases",
        "Thyroid Neoplasm",
        "Thyroid Cancer, Papillary",
        "Carcinoma, Neuroendocrine",
        "Respiratory Tract Neoplasms",
        "Thoracic Neoplasms",
        "Neoplasms by Site",
        "Neoplasms",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Endocrine System Diseases",
        "Endocrine Gland Neoplasm",
        "Head and Neck Neoplasms",
        "Adenocarcinoma, Papillary",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms by Histologic Type",
        "Neuroendocrine Tumors",
        "Neuroectodermal Tumors",
        "Neoplasms, Germ Cell and Embryonal",
        "Neoplasms, Nerve Tissue",
        "Colonic Neoplasms",
        "Colorectal Neoplasms",
        "Intestinal Neoplasms",
        "Gastrointestinal Neoplasms",
        "Digestive System Neoplasm",
        "Digestive System Disease",
        "Gastrointestinal Disease",
        "Colonic Diseases",
        "Intestinal Disease"
      ],
      "interventions": [
        {
          "name": "pralsetinib (BLU-667)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2017-03-17",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03037385"
    },
    {
      "nct_id": "NCT00622674",
      "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2005-11",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622674"
    },
    {
      "nct_id": "NCT01024387",
      "title": "AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumor",
        "Carcinoid Tumor",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-03",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-08",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024387"
    },
    {
      "nct_id": "NCT02192333",
      "title": "Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Cancer Survivor",
        "Depression",
        "Fatigue",
        "Leukemia",
        "Lymphoma",
        "Malignant Bone Neoplasm",
        "Malignant Digestive System Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Male Reproductive System Neoplasm",
        "Pain",
        "Sleep Disorder",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Management of Therapy Complications",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Telephone-Based Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 390,
      "start_date": "2015-08-03",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02192333"
    },
    {
      "nct_id": "NCT05712889",
      "title": "Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "VIP236 (Q3W)",
          "type": "DRUG"
        },
        {
          "name": "VIP236 (Q2W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vincerx Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2023-01-24",
      "completion_date": "2024-10-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Austin, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05712889"
    },
    {
      "nct_id": "NCT00335491",
      "title": "Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Fatigue",
        "Lung Cancer",
        "Lymphoma",
        "Ovarian Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "exercise intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "complementary or alternative medicine procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "fatigue assessment and management",
          "type": "PROCEDURE"
        },
        {
          "name": "physical therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2006-03",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2011-09-30",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00335491"
    },
    {
      "nct_id": "NCT00825955",
      "title": "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Brivanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Best Supportive Care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 587,
      "start_date": "2009-02-17",
      "completion_date": "2017-08-25",
      "has_results": false,
      "last_update_posted_date": "2019-10-09",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Loma Linda, California + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00825955"
    },
    {
      "nct_id": "NCT05565417",
      "title": "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Hormone Receptor Positive Breast Carcinoma",
        "Small Bowel Cancer",
        "Esophageal Cancer",
        "Colorectal Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Hodgkin Lymphoma",
        "Burkitt Lymphoma",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "IMT-009",
          "type": "DRUG"
        },
        {
          "name": "Fruquintinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Immunitas Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2022-11-28",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565417"
    },
    {
      "nct_id": "NCT01176604",
      "title": "Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Yttrium Y 90 Glass Microspheres",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 299,
      "start_date": "2010-08-04",
      "completion_date": "2021-04-09",
      "has_results": false,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-10-27T17:33:55.022Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01176604"
    }
  ]
}